Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.
Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.
The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.
Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.
Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.
Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.
On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.
Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.
As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.
Boston Scientific announced the completion of its acquisition of Lumenis Ltd.'s global surgical business for $1.07 billion, which is expected to generate approximately $200 million in revenue for 2021. This acquisition allows Boston Scientific to integrate Lumenis's advanced laser technology into its urology and otolaryngology offerings, enhancing its growth prospects in Europe and Asia. The deal is projected to be slightly dilutive in 2021, with earnings expected to become accretive in 2022 and beyond as synergies are realized and integration progresses.
Boston Scientific Corporation (NYSE: BSX) received FDA 510(k) clearance for its EXALT Model B Single-Use Bronchoscope, intended for bedside procedures in ICU and OR settings. The bronchoscope enhances suction performance and imaging quality, available in three sizes. With over 1.2 million annual procedures using bronchoscopes in the U.S., the single-use design mitigates infection risks associated with reusable devices. Limited market release is expected soon following the completion of CE marking in May 2021.
Boston Scientific has launched the HI-PEITHO clinical trial, investigating the efficacy of the EkoSonic Endovascular System combined with anticoagulation for treating acute, intermediate-high-risk pulmonary embolism (PE). The trial, enrolling up to 544 patients across 65 sites in the U.S. and Europe, aims to compare outcomes against anticoagulation alone. Nearly one million patients are impacted by PE annually in the U.S. and Europe, emphasizing the trial's significance. The study follows patients for a year to assess adverse events and improve clinical guidelines for PE treatment.
Boston Scientific (NYSE: BSX) received a New Technology Add-on Payment (NTAP) from the U.S. Centers for Medicare & Medicaid Services (CMS) for its EXALT™ Model D Single-Use Duodenoscope, effective October 1, 2021. This reimbursement will enhance access to this technology for Medicare patients, who constitute over 40% of ERCP procedures in the U.S. The duodenoscope aims to reduce infection risks associated with traditional reusable models, aligning with FDA recommendations for more disposable options.
Boston Scientific Corporation (BSX) reported second quarter 2021 net sales of $3.077 billion, a 53.6% year-over-year increase. GAAP net income reached $172 million or $0.12 per share, recovering from a loss of $153 million last year. Adjusted EPS soared to $0.40, beating expectations. Growth was driven by strong sales across segments: MedSurg (64.6%), Rhythm and Neuro (65.0%), and Cardiovascular (51.4%). The company also initiated European launches for new medical devices and expanded its electrophysiology portfolio.
Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. The trial, presented at TVT: The Structural Heart Summit, involved 400 patients with non-valvular atrial fibrillation (NVAF). It showed a rate of ischemic stroke or systemic embolism of 3.4%, significantly better than the 8.7% performance goal. The trial confirms the device's safety and efficacy, with favorable outcomes including no significant complications. The WATCHMAN FLX device has received FDA approval and is widely adopted in the U.S. and Europe.
Boston Scientific Corporation (NYSE: BSX) will host a conference call on July 27, 2021, at 8:00 a.m. EDT to discuss its financial results for Q2 2021. The call will feature Mike Mahoney, CEO, and Dan Brennan, CFO. A news release detailing the financial results will be issued prior to the call. Interested parties can access the live webcast and replay at investors.bostonscientific.com, starting one hour after the call's conclusion.
Boston Scientific Corporation (NYSE: BSX) has announced the election of David S. Wichmann to its board of directors as of June 24, 2021. Wichmann previously served as the CEO of UnitedHealth Group from 2017 to 2021, with a career at the company spanning 23 years. His expertise includes enhancing patient outcomes and reducing healthcare costs. CEO Mike Mahoney expressed optimism about Wichmann's insights contributing to innovation at Boston Scientific. This move emphasizes the company's commitment to strengthening leadership that can drive growth and improve healthcare solutions.
Boston Scientific (NYSE: BSX) announced its decision to acquire the remaining shares of Farapulse, Inc. The acquisition, valued at approximately $295 million for a 73% stake, will enhance Boston Scientific's electrophysiology portfolio by incorporating the FARAPULSE Pulsed Field Ablation (PFA) System for treating cardiac arrhythmias. The deal may expand earnings but is expected to be slightly dilutive to adjusted EPS in 2021 and 2022. The transaction is set to close in Q3 2021, pending customary conditions.
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for its EXALT™ Model B Single-Use Bronchoscope, targeting ICU, OR, and bronchoscopy suite procedures. A limited market release will start in Europe in June 2021. The bronchoscope comes in three sizes and offers enhanced imaging and suction capabilities, addressing infection risks associated with reusable scopes. Over 1.5 million bronchoscopies are performed annually in Europe. This innovation aims to improve patient safety and hospital efficiency, as single-use scopes are preferred for eliminating contamination risks.
FAQ
What is the current stock price of Boston Scientific (BSX)?
What is the market cap of Boston Scientific (BSX)?
What does Boston Scientific Corp. specialize in?
What are the main segments of Boston Scientific?
What recent financial achievement has Boston Scientific announced?
What is the AGENT™ Drug-Coated Balloon (DCB)?
What is the focus of Boston Scientific’s latest clinical trials?
How has Boston Scientific performed financially in 2024?
What are some key products manufactured by Boston Scientific?
How much of Boston Scientific’s sales come from international markets?
Who are Boston Scientific’s customers?
What is Boston Scientific's vision for the future?
